BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Thyroid cancer AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Prognosis
17 results:

  • 1. Novel quantitative immunohistochemistry method using histone H3, family 3B as the internal reference standard for measuring human epidermal growth factor receptor 2 expression in breast cancer.
    Wang J; Xia YC; Tian BX; Li JT; Li HY; Dong H; Li XG; Yu H; Zhu YY; Ma J; Jiang YJ; Jin GZ
    Cancer; 2024 Apr; 130(S8):1424-1434. PubMed ID: 38217532
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Nomogram for preoperative estimation risk of lateral cervical lymph node metastasis in papillary thyroid carcinoma: a multicenter study.
    Zhu J; Chang L; Li D; Yue B; Wei X; Li D; Wei X
    Cancer Imaging; 2023 Jun; 23(1):55. PubMed ID: 37264400
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Evaluation of serum B7-H3 expression, ultrasound and clinical characteristics to predict the risk of cervical lymph node metastases in papillary thyroid carcinoma by nomogram.
    Huang Y; Huang Z; Cai H; Zhuge L; Wang S; Yan D; Zhang X; An C; Niu L; Li Z
    J Clin Lab Anal; 2023 Jan; 37(1):e24811. PubMed ID: 36525343
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Identification and validation of a novel pyroptosis-related lncRNAs signature associated with prognosis and immune regulation of hepatocellular carcinoma.
    Zhang Z; Xia F; Xu Z; Peng J; Kang F; Li J; Zhang W; Hong Q
    Sci Rep; 2022 May; 12(1):8886. PubMed ID: 35614201
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Immune Checkpoint Protein Expression Defines the prognosis of Advanced thyroid Carcinoma.
    Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
    Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated thyroid cancer: Evaluation of the Preclinical Rationale.
    Adam P; Kircher S; Sbiera I; Koehler VF; Berg E; Knösel T; Sandner B; Fenske WK; Bläker H; Smaxwil C; Zielke A; Sipos B; Allelein S; Schott M; Dierks C; Spitzweg C; Fassnacht M; Kroiss M
    Front Endocrinol (Lausanne); 2021; 12():712107. PubMed ID: 34475850
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Comprehensive analysis of pan-cancer reveals potential of ASF1B as a prognostic and immunological biomarker.
    Hu X; Zhu H; Zhang X; He X; Xu X
    Cancer Med; 2021 Oct; 10(19):6897-6916. PubMed ID: 34472711
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Second Malignancies after Radiation Therapy: Update on Pathogenesis and Cross-sectional Imaging Findings.
    Khanna L; Prasad SR; Yedururi S; Parameswaran AM; Marcal LP; Sandrasegaran K; Tirumani SH; Menias CO; Katabathina VS
    Radiographics; 2021; 41(3):876-894. PubMed ID: 33891523
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. DPP4 gene silencing inhibits proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells through suppression of the MAPK pathway.
    Hu X; Chen S; Xie C; Li Z; Wu Z; You Z
    J Endocrinol Invest; 2021 Aug; 44(8):1609-1623. PubMed ID: 33387351
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Efficacy of lenvatinib in treating thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Pharmacother; 2016 Aug; 17(12):1683-91. PubMed ID: 27398740
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. PKM2 regulates chromosome segregation and mitosis progression of tumor cells.
    Jiang Y; Li X; Yang W; Hawke DH; Zheng Y; Xia Y; Aldape K; Wei C; Guo F; Chen Y; Lu Z
    Mol Cell; 2014 Jan; 53(1):75-87. PubMed ID: 24316223
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis.
    Yang W; Xia Y; Hawke D; Li X; Liang J; Xing D; Aldape K; Hunter T; Alfred Yung WK; Lu Z
    Cell; 2012 Aug; 150(4):685-96. PubMed ID: 22901803
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
    Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
    Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma.
    Bravo SB; García-Rendueles ME; Seoane R; Dosil V; Cameselle-Teijeiro J; López-Lázaro L; Zalvide J; Barreiro F; Pombo CM; Alvarez CV
    Clin Cancer Res; 2005 Nov; 11(21):7664-73. PubMed ID: 16278386
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Pituitary tumor transforming gene and fibroblast growth factor-2 expression: potential prognostic indicators in differentiated thyroid cancer.
    Boelaert K; McCabe CJ; Tannahill LA; Gittoes NJ; Holder RL; Watkinson JC; Bradwell AR; Sheppard MC; Franklyn JA
    J Clin Endocrinol Metab; 2003 May; 88(5):2341-7. PubMed ID: 12727994
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR.
    Sheils OM; O'Leary JJ; Sweeney EC
    J Pathol; 2000 Sep; 192(1):32-6. PubMed ID: 10951397
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Genetic alterations in thyroid carcinoma associated with familial adenomatous polyposis: clinical implications and suggestions for early detection.
    Cetta F; Olschwang S; Petracci M; Montalto G; Baldi C; Zuckermann M; Mariani Costantini R; Fusco A
    World J Surg; 1998 Dec; 22(12):1231-6. PubMed ID: 9841749
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.